Kynurenine and uric acid levels in chronic myeloid leukemia patients

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-6

  Vonka, Vladimir ^a   Humlova, Zuzana ^b   Klamova, Hana ^a   Kujovska Krcmova, Lenka ^c,d   Petrackova, Martina ^a   Hamsikova, Eva ^a   Krmencikova Fliegl, Monika ^a   Duskova, Martina ^a   Roth, Zdenek ^e  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^e State Institute of Health   (Czech Republic)

Author keywords

3 dioxygenase; Chronic myeloid leukemia; Indoleamine 2; Kynurenine; Tryptophan metabolism; Uric acid

Indexed keywords

ALPHA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; TUMOR VOLUME;

EID: 84924310773     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.992646     Document Type: Article

References (53)

1. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007; 67:7082-7; PMID:17671174; http://dx.doi.org/10.1158/0008-5472.CAN-07-1872
2. Capece L, Arrar M, Roitberg AE, Yeh SR, Marti MA, Estrin DA. Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase. Proteins 2010; 78:2961-72; PMID:20715188; http://dx.doi.org/10.1002/prot.22819
3. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 1991; 294:425-35; PMID:1722946; http://dx.doi.org/10.1007/978-1-4684-5952-4_39
4. Danesch U, Gloss B, Schmid W, Schutz G, Schule R, Renkawitz R. Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoid-responsive elements. EMBO J. 1987; 6:625-30; PMID:3582368
5. Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem. 1986; 261:3648-53; PMID:2419335
6. Muller N, Schwarz MJ. Immune System and Schizophrenia. Curr. Immunol. Rev. 2010; 6:213-20; PMID:21057585; http://dx.doi.org/10.2174/157339510791823673
7. Dankers AC, Mutsaers HA, Dijkman HB, van den Heuvel LP, Hoenderop JG, Sweep FC, Russel FG, Masereeuw R. Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). Biochim. Biophys. Acta 2013; 1832:1715-22; PMID:23665398; http://dx.doi.org/10.1016/j.bbadis.2013.05.002
8. Mackenzie CR, Gonzalez RG, Kniep E, Roch S, Daubener W. Cytokine mediated regulation of interferongamma-induced IDO activation. Adv. Exp. Med. Biol. 1999; 467:533-9; PMID:10721097; http://dx.doi.org/10.1007/978-1-4615-4709-9_66
9. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-3; PMID:9712583; http://dx.doi.org/10.1126/science.281.5380.1191
10. Blaschitz A, Gauster M, Fuchs D, Lang I, Maschke P, Ulrich D, Karpf E, Takikawa O, Schimek MG, Dohr G et al. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS. One. 2011; 6:e21774; PMID:21755000; http://dx.doi.org/10.1371/journal.pone.0021774
11. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, Puccetti P, Romani L, Grohmann U. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 2009; 183:6303-12; PMID:19841163; http://dx.doi.org/10.4049/jimmunol.0901577
12. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl. Acad. Sci. U. S. A 1988; 85:1242-6; PMID:3124115; http://dx.doi.org/10.1073/pnas.85.4.1242
13. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003; 4:1206-12; PMID:14578884; http://dx.doi.org/10.1038/ni1003
14. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900; PMID:18317452; http://dx.doi.org/10.1038/onc.2008.35
15. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 2009; 183:2475-83; PMID:19635913; http://dx.doi.org/10.4049/jimmunol.0900986
16. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010; 185:3190-8; PMID:20720200; http://dx.doi.org/10.4049/jimmunol.0903670
17. Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr. Med. Chem. 2011; 18:2240-6; PMID:21517755; http://dx.doi.org/10.2174/092986711795656045
18. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006; 176:6752-61; PMID:16709834; http://dx.doi.org/10.4049/jimmunol.176.11.6752
19. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003; 171:1652-5; PMID:12902462; http://dx.doi.org/10.4049/jimmunol.171.4.1652
20. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death. Differ. 2002; 9:1069-77; PMID:12232795; http://dx.doi.org/10.1038/sj.cdd.4401073
21. Song H, Park H, Kim J, Park G, Kim YS, Kim SM, Kim D, Seo SK, Lee HK, Cho D et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol. Lett. 2011; 136:187-93; PMID:21277902; http://dx.doi.org/10.1016/j.imlet.2011.01.009
22. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J. Am. Coll. Surg. 2009; 208:781-7; PMID:19476837; http://dx.doi.org/10.1016/j.jamcollsurg.2008.12.018
23. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, De PE, Uyttenhove C, Wouters J, Masereel B et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A 2012; 109:2497-502; PMID:22308364; http://dx.doi.org/10.1073/pnas.1113873109
24. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83:1457-66; PMID:14563947; http://dx.doi.org/10.1097/01.LAB.0000090158.68852.D1
25. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007; 214:8-14; PMID:17191041; http://dx.doi.org/10.1159/000096906
26. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 2006; 12:1144-51; PMID:16489067; http://dx.doi.org/10.1158/1078-0432.CCR-05-1966
27. Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, Durelli I, Horenstein AL, Fiore F, Massaia M et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007; 21:353-5; PMID:17170728; http://dx.doi.org/10.1038/sj.leu.2404485
28. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008; 134:1247-53; PMID:18438685; http://dx.doi.org/10.1007/s00432-008-0395-1
29. Feder-Mengus C, Wyler S, Hudolin T, Ruszat R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A, Gasser TC et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur. J. Cancer 2008; 44:2266-75; PMID:18619832; http://dx.doi.org/10.1016/j.ejca.2008.05.023
30. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin. Exp. Metastasis 2009; 26:1005-12; PMID:19802733; http://dx.doi.org/10.1007/s10585-009-9290-7
31. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 2010; 67:361-5; PMID:19487045; http://dx.doi.org/10.1016/j.lungcan.2009.05.001
32. de Jong RA, Nijman HW, Boezen HM, Volmer M, Ten Hoor KA, Krijnen J, van der Zee AG, Hollema H, Kema IP. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int. J. Gynecol. Cancer 2011; 21:1320-7; PMID:21720257
33. Bonanno G, Mariotti A, Procoli A, Folgiero V, Natale D, De RL, Majolino I, Novarese L, Rocci A, Gambella M et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J. Transl. Med. 2012; 10:247; PMID:23232072; http://dx.doi.org/10.1186/1479-5876-10-247
34. Lindstrom V, Aittoniemi J, Jylhava J, Eklund C, Hurme M, Paavonen T, Oja SS, Itala-Remes M, Sinisalo M. Indoleamine 2,3-dioxygenase activity and expression in patients with chronic lymphocytic leukemia. Clin. Lymphoma Myeloma. Leuk. 2012; 12:363-5; PMID:22981691; http://dx.doi.org/10.1016/j.clml.2012.06.001
35. Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 2013; 72:1031-8; PMID:23426156; http://dx.doi.org/10.1227/NEU.0b013e31828cf945
36. Choe JY, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, Oh S, Kim JE. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC. Cancer 2014; 14:335; PMID:24886161; http://dx.doi.org/10.1186/1471-2407-14-335
37. Ye J, Liu H, Hu Y, Li P, Zhang G, Li Y. Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch. 2013; 462:73-81; PMID:23179760; http://dx.doi.org/10.1007/s00428-012-1340-x
38. Vonka V. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy. 2010; 2:227-41; PMID:20635930; http://dx.doi.org/10.2217/imt.10.2
39. Vonka V. Comments on therapeutic cancer vaccines. Immunotherapy. 2012; 4:133-5; PMID:22339454; http://dx.doi.org/10.2217/imt.11.173
40. Awad M, Pravica V, Perrey C, El GA, Yonan N, Sinnott PJ, Hutchinson IV. CA repeat allele polymorphism in the first intron of the human interferongamma gene is associated with lung allograft fibrosis. Hum. Immunol. 1999; 60:343-6; PMID:10363726; http://dx.doi.org/10.1016/S0198-8859(98)00133-5
41. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor SP, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011; 117:2200-10; PMID:21079151; http://dx.doi.org/10.1182/blood-2010-06-288498
42. Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH. Natural CD4C T-cell responses against indoleamine 2,3-dioxygenase. PLoS. One. 2012; 7:e34568; PMID:22539948; http://dx.doi.org/10.1371/journal.pone.0034568
43. Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, Andersen MH. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res. 2011; 71:2038-44; PMID:21406395; http://dx.doi.org/10.1158/0008-5472.CAN-10-3403
44. Fotopoulou C, Sehouli J, Pschowski R, VON HS, Domanska G, Braicu EI, Fusch G, Reinke P, Schefold JC. Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. Anticancer Res. 2011; 31:2629-35; PMID:21778315
45. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr. Opin. Hematol. 2001; 8:131-6; PMID:11303144; http://dx.doi.org/10.1097/00062752-200105000-00001
46. Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol. Psychiatry 2011; 70:175-82; PMID:21277567; http://dx.doi.org/10.1016/j.biopsych.2010.12.006
47. Humlova Z, Klamova H, Janatkova I, Sandova P, Sterzl I, Sobotkova E, Hamsikova E, Haskovec C, Pisacka M, Cetkovsky P et al. Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment. Folia Biol. (Praha) 2006; 52:47-58; PMID:17089915
48. Humlova Z, Klamova H, Janatkova I, Malickova K, Kralikova P, Sterzl I, Roth Z, Hamsikova E, Vonka V. Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clin. Dev. Immunol. 2010; 2010:137-320; PMID:21197073; http://dx.doi.org/10.1155/2010/137320
49. Curreli S, Romerio F, Mirandola P, Barion P, Bemis K, Zella D. Human primary CD4 C T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase. J. Interferon Cytokine Res. 2001; 21:431-7; PMID:11440641; http://dx.doi.org/10.1089/107999001750277916
50. Nagai A, Kubota M, Tang L, Adachi S, Usami I, Matsubara K. Hyperuricemia in pediatric malignancies before treatment. Nucleosides Nucleotides Nucleic Acids 2011; 30:1060-5; PMID:22132957; http://dx.doi.org/10.1080/15257770.2011.591745
51. Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, Kishi S, Tai K, Hosono N, Tasaki T et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013; 33:3947-51; PMID:24023333
52. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012; 1:1460-8; PMID:23264892; http://dx.doi.org/10.4161/onci.21716
53. Krcmova L, Solichova D, Melichar B, Kasparova M, Plisek J, Sobotka L, Solich P. Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. Talanta 2011; 85:1466-71; PMID:21807211; http://dx.doi.org/10.1016/j.talanta.2011.06.027